title: Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
authors.affiliation: From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital - both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University; and Ocean State Research Institute, Providence VA Medical Center - all in Providence, RI (R.J.S.); and the Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, and CPC Clinical Research - both in Aurora (W.R.H.). All three authors participated as voting members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on alirocumab, and Drs. Smith and Hiatt participated as voting members of the Advisory Committee meeting on evolocumab.
authors.forename: Brendan M
authors.initials: BM
authors.lastname: Everett
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Smith
authors.forename: William R
authors.initials: WR
authors.lastname: Hiatt
mesh_terms: D026683:Advisory Committees; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D017277:Drug Approval; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D012697:Serine Endopeptidases; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases; C577155:evolocumab; C571059:alirocumab